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1PART ONE
2ABBREVIATIONS
CSCR-CENTRAL SEROUS CHORIORETINOPATHY
PED-PIGMENT EPITHELIAL DETACHMENT
FAZ-FOVEAL AVASCULAR ZONE
FFA-FUNDUS FLUORESCEIN ANGIOGRAPHY
ICG-INDOCYANINE GREEN ANGIOGRAPHY
OCT-OPTICAL COHERENCE TOMOGRAPHY
CNVM-CHOROIDAL NEOVASCULAR MEMBRANE
RPE-RETINAL PIGMENT EPITHELIUM
IS-OS-INNER SEGMENT-OUTER SEGMENT JUNCTION
NSAIDS-NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
3INTRODUCTION
CENTRAL SEROUS CHORIORETINOPATHY is a disease
characterized by spontaneous serous macular detachment of unknown
etiology, usually self-limiting but often recurs.
It was first described by VonGraefe in 1866 and termed it “central
recurrent retinitis”, “central angiopathic retinopathy”.1
Kitahara in 1936 described it as chorioretinitis centralis serosa.
Walsh and solan described it as Idiopathic flat detachment of
macula.
In 1955 Bennet coined the term central serous retinopathy.
Klein and Maumenee used fundus fluorescein angiography to
observe leaks at the level of retinal pigment epithelium.
In 1967 Gass provided the pathogenesis and labelled it as
“Idiopathic central serous choroidopathy”.
4ANATOMY OF MACULA
Macula is that portion of the posterior pole with minimum two
layers of nuclei in the ganglion cell layer and contains xanthophyll
pigment. There is no anatomical landmark to define this zone on clinical
examination or on morphological basis. It is approximately a circle with
a radius of 2.75mm centered at fovea (5.5mm in diameter).3
Fovea centralis is the depression in the inner retinal surface in the
centre of the macula and is 1.5mm in diameter.
Foveola is 0.35mm in diameter. It is situated 4mm temporal and
0.8mm inferior to the optic nerve head. Rod-Cone ratio is about 1:2 in
this region.
A small depression in the centre of foveola is called umbo.
Parafoveal zone is an area measuring 0.5 mm surrounding the
fovea. Rod-Cone ratio is about 1:1. Perifoveal area is 1.5mm wide zone
surrounding parafoveal area.3
Retinal pigment epithelial cells at the fovea are taller, thinner,
contain more and large pigment granules than elsewhere in the fundus
and this makes the macula appear darker than the rest of fundus.
5Blood supply of Macula
The macula region get its blood supply by small twigs from the
superior and inferior branches of the central retinal artery. In 20% of
individuals cilioretinal artery, a branch from the ciliary system of
vessels supply the macula. Capillaries are arranged as three layered in
the macula, and they are reduced to single layer in the perifoveal area
and in centre is the capillary free zone of 400-600 µm in diameter.3
BLOOD- RETINAL BARRIER
Outer Blood Retinal Barrier
This is formed by the tight junctions (Zonulae occludens and
Zonulae adherens) of retinal pigment epithelial cells.
Inner Blood-Retinal barrier
The endothelial cells of retinal capillaries bound together, about
the lumen by intercellular junctions of zonula occludens type and forms
the inner Blood-Retinal barrier.3
6RPE and CHOROID
Retinal pigment epithelial cells are densely adherent to the
underlying Bruch’s membrane of choroid. The oncotic pressure, exerted
by the intravascular proteins of choriocapillaries and the intracellular
pumping mechanism within the RPE maintains the dehydrated state of
the sub-retinal space.
The Choroid is supplied by the ciliary system that is concentrated
in the macula and peripapillary region. They form rich anastomotic
network and there is a rapid transformation from arterioles to capillaries.
In the macula, there is a lobular pattern of arrangement, which facilitates
rapid blood flow.3
7MICROANATOMY OF MACULA
Retina, at the macula consists of 3 types of cells and their synapses
arranged from without inwards in the following layers,
? Retinal pigment epithelium
? Layer of Rods and Cones
? External limiting membrane
? Outer nuclear layer
? Outer plexiform layer
? Inner nuclear layer
? Inner plexiform layer
? Ganglion cell layer (multilayered in comparison to rest of
retina)
? Nerve fibre layer
? Internal limiting membrane.3
In Central Serous Chorioretinopathy there is a split between the
RPE and rest of the layers of neurosensory retina at the macula.
8FOVEA CENTRALIS
This region is predominated by cones and their axons are
arranged obliquely, forming the henle’s layer. It contains 10% of the
cone population in the whole retina.
FOVEOLA
This region of retina contains cones and their nuclei covered by
thin internal limiting membrane. Remaining retinal layers are absent in
the macula.3
9EVALUATION OF MACULAR DISEASES
SLIT LAMP BIOMICROSCOPY
It ulilizes high power convex lenses to obtain wide field of view
of the fundus which is vertically inverted and laterally reversed, It
provides high magnification with stereopsis to detect macular disease.4
AMSLER GRID
It evaluates the 20° of visual field centred on fixation, and hence
useful in screening and monitoring the macular disease. There are 7
charts. Chart 1is most commonly used. This chart consists of white grid
on black background, with 400 smaller 5mm squares, each square
subtends an angle of 1° when viewed at 33cm. Each eye is checked
individually, with the chart held at 33 cm, priorly patients should be
corrected for the presbyopia. Patients are asked to maintain fixation on
the central dot and comment on the four corners, of the sides, any
missing areas on chart and wavy lines.4
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FUNDUS FLUORESCEIN ANGIOGRAPHY
Fluorescence is the property of certain molecules to absorb light
of shorter wavelength and emit light of longer wavelength. This is the
principle in fundus fluorescein angiography and is extremely valuable in
evaluation of macular diseases.4,5
Sodium fluorescein, an orange water soluble dye, about 3ml of
25% is injected intravenously, 85% of it is bound to plasma proteins and
remains intravascular, passage of dye through the retinal and choroid
circulation is studied through photographic surveillance.4,5
PHASES IN FFA
? Choroidal phase
? Arterial phase
? Arteriovenous phase
? Venous phase
? Recirculation phase.
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Causes of Hyperfluorescence
Autofluorescence, Pseudofluorescence, Window defect, Pooling,
leakage and staining.
Causes of Hypofluorescence
Masking of Retinal fluorescence, masking of choroidal
fluorescence, Filling defects.4,5
INDOCYANINE GREEN ANGIOGRAPHY
Masking  effect  of  RPE prevents the delineation of choroidal
vasculature in FFA. ICG utilizes the near infrared light for deep
penetration. ICG is 98% protein bound and does not leak through the
fenestrations of choriocapillaries and remains within the choroidal
vasculature and helps to study the choroidal disease.
A dose of 25-50mg in 1-2ml is injected through the antecubital
vein.
Phases of choroidal fluorescence
? Early phase (upto 60 sec)
? Shows choroidal arteries and early perfusion of watershed
zone.
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? Early mid-phase (1-3mins)
? Shows Choroidal veins and Retinal vessels.
? Late mid-phase (3-15mins)
? Shows fading of choroidal vessels and retinal vessels still
visible.
? Late phase (15-45mins)
? Shows hypofluorescence of choroidal vessels and gradual
fading of diffuse hyperfluorescence.
Causes of hyperfluorescence
? Window defect
? Abnormal retinal or choroidal vessels
? Leakage
Causes of hypofluorescence
? Blockage
? Filling defects
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ICG is indicated in macular diseases like CNVM, CSCR, in
Polypoidal choroidal vasculopathy, PED, posterior uveitis, choroidal
tumour and so on.4
OPTICAL COHERENCE TOMOGRAPHY
OCT is a noninvasive, noncontact imaging system provides high
resolution cross-sectional images of the retina, optic nerve head and the
vitreous.
Principle
OCT is based on imaging of reflected light (near infrared light),
analogous to B-Scan, the only difference is that OCT uses the principle
of low coherence interferometry measures the optical rather than
acoustic or radio wave reflectivity.
OCT is indicated to differentiate the lamellar and full thickness
macular hole, to determine the treatment option in CNVM, monitoring
the course of CSCR and locate the area of leak, retinal thickness map
and so on.6
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HIGH REFLECTIVITY
? Nerve Fibre Layer (Normal)
? RPE-Choriocapillaries (Normal)
? Pigment accumulation
? Naevus
? Neovascularization
? RPE hypertrophy
MEDIUM REFLECTIVITY
? Plexiform Layer (Normal)
LOW REFLECTIVITY
? Nuclear Layer (Normal)
? Photoreceptors (Normal)
? Retinal Edema
? Cystoid Edema
? Cavity
? Cyst
? Pigment Epithelial Detachment
? Serous Retinal Detachment10
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EPIDEMIOLOGY OF CENTRAL SEROUS
CHORIORETINOPATHY
Central serous chorioretinopathy is characterized by an idiopathic
circumscribed serous retinal detachment usually confined to central
macula, caused by the leakage of fluid through retinal pigment
epithelium.
CSCR is most common in middle age adults between 20-45 years,
but cases as old as 50yrs and as young as 7yrs are reported.8 CSCR
affects men more frequently than women (male to female ratio 6:1).9
Caucasians are affected frequently and Afro- americans the least.
Type A personality, patients on long term steroids in any form (topical,
oral, inhalational or injectable) systemic steroids in organ transplant
patients, rarely following PST and intravitreal steroids, pregnancy,
alcohol, antibiotics, untreated hypertension.10
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PATHOPHYSIOLOGY OF CSCR
Various theories have been put forward and yet to evolve, as we
understand the disease better as investigation advances.
FFA shows serous detachment which is due to the accumulation
of fluid from the choroid through a precisely located defect in the RPE.
ICG angiography gives a new graphic abnormality of choroidal
circulation in patients with central serous chorioretinopathy.
Raised Sympathomimetics levels in circulation
Increased venous congestion of choroidal vasculature
Multifocal areas of hyperpermeability in choroidal circulation
and increased tissue hydrostatic pressure within the vasculature leads
to pigment epithelial detachment
Disruption of retinal pigment epithelial barrier
Abnormal egress of fluid under the retina leading to CSCR.11,12
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HISTOPATHOLOGY OF CSCR
Shows focal areas of degenerated RPE with adjacent damaged
choriocapillary endothelial cells.
The presence of subretinal fibrin indicates alteration in the
permeability of choriocapillaries permitting the molecules as large as
fibrinogen to leak.13
18
CLINICAL FEATURES OF CSCR
SYMPTOMS
? Minimal blurring of vision
? Metamorphopsia
? Dyschromatopsia
? Hypermetropisation
? Central scotoma
? Loss of contrast sensitivity
SIGNS
Fundus Examination shows localized detachment of retina at the
macula appearing as delineated transparent blister at the posterior
pole.(FIG-1)
Pigment epithelial detachment can also be seen.14Subretinal
deposits are occasionally seen, these occur in four forms which includes
fibrin, lipid, macrophages and outer photoreceptor segments.Hourglass
pattern of RPE abnormalities seen in chronis CSCR.(FIG-2)
Subretinal lipid and macrophages occur in chronic CSCR
patients.15Multifocal serous detachment rarely reported in some patients
(FIG-3,4)
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FIGURE-1-SEROUS DETACHMENT IN MACULA
FIGUREP-2-CSR WITH HOURGLASS PATTERN OF
RPE DEFECTS
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FIGURE-3 MULTIFOCAL DETACHMENT
FIGURE-4 MULTIFOCAL DETACHMENT IN FFA
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IMAGING MODALITIES IN CSCR
Fundus Fluorescein Angiography
The typical, most common dye leakage pattern in CSCR is “Ink
blot pattern”(FIG-5) present in 90% of cases.16,17
Others include “Smoke stack pattern”(FIG-6,7,8) its also termed
as mushroom or umbrella pattern.
The reason for Smoke stack pattern is due to convection current
and differences in protein gradient of fluid in the subretinal space.16
The dye spreads in subretinal space in late phase of FFA and
shows pooling of the dye in the detached area.
In acute cases, increased autofluorescence noted at the leakage
site and in the areas of retinal detachment. This was attributed to
increased metabolic activity of RPE.
In chronic cases, autofluorescence is due to subretinal granular
deposits.18,19
22
FIGURE-5 INK BLOT PATTERN IN LATE PHASE
FIGURE-6 SMOKE STACK PATTERN –EARLY PHASE
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FIGURE-7 SMOKE STACK PATTERN IN MID-PHASE
FIGURE-8 SMOKE STACK PATTERN IN LATE-PHASE
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Indocyanine Green Angiography
ICG demonstrates hyperpermeability of the choriodal vasculature,
best seen in mid-phase of the angiogram.
In the late phase, leaked dye appears to disperse, producing a
characteristic appearance of hyperfluorescent  patches in the choroid
with silhouetting of the large choroidal vessels.
Young patients  have  PED as  a  forme  fruste  of  CSCR where  the
underlying choroidal hyperpermeability may cause elevation of RPE
without causing a breakthrough leak.20,8
Optical Coherence Tomography
OCT is effective in diagnosing and quantifying the serous
detachment of retina.
OCT shows bullae of subretinal fluid with near normal
neuroretinal architecture overlying it(FIG-9).
Retinal atrophy may be noted in some patients.Pigment epithelial
detachment is noted in some patients.(FIG-10).
Spectral domain OCT additionally demonstrates elongation of
photoreceptor outer segment and IS-OS junction distance,
hyperreflectivity of outer nuclear and inner plexifom layer and choroidal
thickening in CSCR.21.22
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FIGURE-9SEROUS DETACHMENT OF MACULA
FIGURE-10 SEROUS DETACHMENT WITH PED
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DIFFERNTIAL DIAGNOSIS OF CSCR
? Harada’s disease
? Posterior scleritis
? Sympathetic ophthalmitis
? Optic disc pit
? Choroidal neovascular membrane
? Choroidal melanoma
? Choroidal hemangioma
? Benign reactive hyperplasia of the choroid
? Uveal effusion syndrome
? Polypoidal choroidal vasculopathy
? Malignant hypertension
? Toxemia of pregnancy.15
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TREATMENT MODALITIES IN CSCR
CSCR is self resolving in most cases with visual recovery of
20/25 or better.
Patients advised to avoid the precipitating causes of the disease.
Systemic steroids in any form of administration (oral, inhalational,
topical, ointments, etc)23,24
Majority of patients with CSCR were associated with raised
serum cortisol level.25
Factors Determining The Treatment Modality
? Visual acuity
? Recurrences
? Visual needs
Its generally recommended to observe a patient with CSCR for 3
months.
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Treatment options include:
? Laser photocoagulation26
? Photodynamic therapy
? Transpupillary thermotherapy
? Medical treatment
? Meditation and yoga
Indications for early laser photocoagulation:
? Multifocal CSCR
? Bullous sensory detachment
? Visual loss in fellow eye due to CSCR.
? Recurrent CSCR
? Diffuse RPE decompensation
? Subretinal deposits of fibrin and lipid
? Patient on steroids where therapy cannot be withdrawn
? All patients with CSCR where leak is not threatening the
fovea30,31
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Laser Photocoagulation
Watze et al reported that laser photocoagulation hastened the
resolution of CSCR from 25 wks to 5wks.28
Most common laser used is
? Argon green
? Infrared laser
? Micropulsed diode laser
Technique
? Foci of leakage is localized with the help of FFA, 72 hrs before
the procedure.
? Argon green Laser of spot size 50-100µm.
? Duration of 0.05-0.1sec
? Power of 70-80mW (to produce minimally visible burn of RPE)
? Laser is targeted at the site of leakage 27,28
? Recently subthreshold diode  laser can be tried for leaks within
500µm of the fovea.32,33
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COMPLICATIONS OF LASER
? Scotoma
? Laser scars extend to fovea and cause visual detoriation
? Choroidal neovascularisation
The role of laser treatment is limited to hastening the resolution of
symptomatic disease.
Photodynamic Therapy And Transpupillary Thermotherapy
? Indicated in chronic disease.34,35
? Scarring  and collateral damage is the major drawback.
MEDICAL TREATMENT
? Beta blockers36
? Ketoconazole
? Multivitamin supplements
? Topical NSAIDS
All were tried with no conclusive benefits. Lifestyle modification
like meditation, yoga can be tried, cessation of smoking should be
stressed.
31
Prognosis
The prognosis for majority of the patients with typical CSCR is
excellent with most patients having spontaneous resolution of macular
detachment with return of visual acuity within 6 months, approximately
5% may fail to recover 6/9 vision or better.
Some patients may develop permanent visual loss of 6/60 or less.
Resolution of serous detachment demonstrates the evidence of irregular
depigmentation.
The long term visual prognosis is good, approximately 20 -30%
will have one or more recurrences.
32
PART TWO
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AIM OF THE STUDY
? To study the FFA pattern and use of OCT (Optical coherence
tomography) in CSCR.
? Study the effectiveness of early laser photocoagulation in CSCR
patients with extrafoveal leakage in terms of visual acuity and
central macular thickness and comparing with the control group.
? To study the epidemiology (incidence, recurrence, persistent
cases) of CSCR.
? To study the association of CSCR with the use of steroids in any
form (systemic, inhalers, ointment etc.,)
34
MATERIALS AND METHODS
This study was conducted in Regional Institute of Ophthalmology
and Government Ophthalmic Hospital, Egmore, Chennai, from
November 2009 to November 2011 for a period of 2 years. This is a
single blind randomised prospective and retrospective inteventional
clinical study.
INCLUSION CRITERIA
All new and review cases attending the Ophthal OPD with
central  serous  retinopathy  diagnosed clinically.
EXCLUSION CRITERIA
1. Patients with ocular infective and inflammatory condition,
2. Patients with diabetes,
3. Patients with collagen vascular disease
METHODOLOGY
? History,
? Visual  acuity,
? Fields,
? Retinoscopy,
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? Slit lamp examination,
? Amsler  grid ,
? Fundus examination with90D & IDO
? FFA
? OCT
Patients diagnosed clinically as CENTRAL SEROUS
CHORIORETINOPATHY were further analysed by taking, a brief
history about the onset and duration of symptoms, history of recurrences
(similar presentation in the same or the other eye) about the steroid
usage in any form, patients were then subjected to a detailed systemic
and ophthalmic evaluation.
OCT and FFA was done for all cases and leakage site identified.
Patients with leakage in the foveal and juxtafoveal region(within 375
micrometer from centre of fovea) were isolated from the intervention.
Total number of patients reviewed with old records and diagnosed
newly as CSCR were 50. Patients(Samples) with first incidence of
CSCR and having FFA picture showing single site leakage which is
375µm away from the fovea were randomly divided into two subgroups
by simple randomization.
Sample size was 30.
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Subgroup1
About 15 patients from total of 30 were assigned randomly as
subgroup1(study group) subjected to early laser photocoagulation.
Subgroup 2
Remaining 15 patients who were assigned as subgroup2 (control
group)  given placebo treatment.
Both the subgroups were subjected for visual acuity by snellen
chart and central macular thickness documentation using OCT  before
and after early laser photocoagulation or placebo treatment as assigned
previously.
During follow up visits at 4 weeks and 12 weeks visual acuity and
central macular thickness  post laser/post placebo treatment were  noted.
In every follow up visits the following parameters were assessed
? Best corrected visual acuity
? Amsler  grid
? Fundus  examination
? OCT
37
OBSERVATION AND ANALYSIS
1. AGE DISTRIBUTION
Table - 1
AGE NO PERCENTAGE
21-30 15 30%
31-40 25 50%
41-50 10 20%
0
10
20
30
40
50
60
21-30 31-40 41-50
21-50 yrs is the predominant age group (50%) affected in our
study. Gass et al in his study also showed predominant involvement
between age groups 20 and 45 years.11
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2. SEX DISTRIBUTION
Table - 2
Sex No. of Cases Percentage
Male 45 90%
Female 5 10%
In our study males were predominantly affected (90%) compared
to females.
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3 LATERALITY
Table - 3
EYE NO PERCENTAGE
RIGHT 23 46%
LEFT 26 52%
BOTH 1 2%
0%
10%
20%
30%
40%
50%
60%
RIGHT EYE LEFT  EYE BOTH EYE
LATERALITY
LATERALITY
In our study though the incidence of Central serous retinopathy
was more in the left eye (52%), there was no significant difference
between the eyes involved and there is no predilection for the eye
involvement.
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4.    PRESENTING COMPLAINTS
Table - 4
All  patients presented with defective vision
Associated findings Percentage
Central  scotoma 30 (60%)
Metamorphopsia 20 (40%)
Micropsia 0
central
scotoma
metamorphopsia
In 60% of patients central scotoma was the predominant
presenting complaint.
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5. EPIDEMIC INDICES
Table - 5
EPIDEMIC INDICES NO PERCENTAGE
Newly diagnosed 30 60%
Recurrent Cases 15 30%
Persistent Cases 5 10%
0%
10%
20%
30%
40%
50%
60%
70%
new cases recurrent case persistent cases
In our study the incidence of first onset of CSCR was 60% and
recurrence of the disease in the same or other eye was 30%.In 10% the
disease was present for more than 4 months. Gass et al., observed
recurrence in 20-30% of  the patients.11
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6. INTERVAL
Table - 6
INTERVAL NO PERCENTAGE
<6months 8 53.33%
6months-18months 4 26.67%
18months-36months 3 20%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
<6months 6-18months 18-36months
Recurrence rate of CSCR within a period of 6 months was seen in
53.33%.
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7. ASSOCIATION  WITH  STEROIDS
Table - 7
STEROID USAGE NO PERCENTAGE
PRESENT 5 10%
ABSENT 45 90%
Steroid usage in our study was noted in only 10% of patients.
Heimovici R,GragsudassEs, Dukes JS,Sjaarda RN,Eliott observed the
association of steroids in CSCR patients.23
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8. VISUAL ACUITY
Table - 8
VISION NO PERCENTAGE
6/6-6/12 12 24%
6/12-6/24 26 52%
6/24-6/60 10 20%
6/60 2 4%
0%
10%
20%
30%
40%
50%
60%
6/6-6/12 6/18-6/24 6/36-6/60 <6/60
Visual acuity of <6/12 was seen in 24% of patients at presentation
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9. FUNDUS  FLUORESCEIN ANGIOGRAPHY PATTERNS
Table - 9
FFA PATTERN NO PERCENTAGE
INK BLOT APPEARANCE 25 50%
SMOKE STACK APPEARANCE 14 28%
RETINAL PIGMENT EPITHELIAL
CHANGES WITH NO LEAK
5 10%
ASSOCIATION WITH PED 5 10%
MULTIFOCAL CSR 1 2%
0%
10%
20%
30%
40%
50%
60%
INK BLOT SMOKE STACK RPE CHANGES MULTIFOCAL
LEAK
ASSOCIATION
WITH PED
Ink blot pattern is the predominant pattern in 50% of patients.
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10. OPTICAL COHERENCE TOMOGRAPHY
Table - 10
OCT PATTERN NO PERCENTAGE
ASSOCIATION WITH PED 6 12%
SEROUS DETACHMENT
QUANTIFICATION
30 60%
0%
10%
20%
30%
40%
50%
60%
70%
ASSOCIATION WITH
PED
SEROUS
DETACHMENT
QUANTIFICATION
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11. LOCATION OF LEAK
Table - 11
SITE OF LEAK NO PERCENTAGE
FAZ 20 40%
STQ 8 16%
SNQ 9 18%
ITQ 10 20%
INQ 3 6%
FAZ
ITQ
SNQ
STQ
INQ
FAZ
ITQ
SNQ
STQ
INQ
Leakage within 500µm of fovea was seen in 40% of patients.
Bennet, G., observed that the overall incidence of leakage points was
greatest in the upper nasal quadrant, followed by lower nasal quadrant,
the upper temporal quadrant and the lower temporal quadrant,in
decreasing order of frequency.13
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SUBGROUP ANALYSIS
TREATMENT
30 patient with first onset of Central Serous Chorioretinopathy for
whom the FFA and OCT showed evidence of leakage 375 µm away
from fovea were randomly divided into two groups .
Subgroup 1
15 randomly selected patients were subjected to laser
photocoagulation with Semiconductor green dye laser of 532nm with
laser parameters
? 100µm-200µm spot size,
? 100mw-150mw power,
? 0.1-0.2 seconds duration.
Subgroup 2
The remaining 15 patients were given placebo treatment and
observed. Visual acuity using snellens chart and Central macular
thickness of serous detachment using OCT of both group was observed
before and after laser treatment and patients were followed up at  4th
and 12th week.
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12. MACULAR THICKNESS PRE-TREATMENT (Study and
control group)
Table - 12
MACULAR
THICKNESS
PRE-TREATMENT
SUBGROUP 1
PRE-TREATMENT
SUBGROUP 2
200-300µm 3(20%) 5(33.33%)
301-400 µm 7(46.67%) 5(33.33%)
401-500 µm 2(13.33%) 2(13.33%)
>500 µm 3(20%) 3(20%)
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
200-300µm 301-400µm 401-500µm >500µm
subgroup1
subgroup2
The average pretreatment macular thickness in the subgroup 1
was 403.60 µm and in subgroup 2 was 421.87µm.The predominant
range of thickness in the two groups were 301-400µm.
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13. VISUAL ACUITY POST TREATMENT AT 4TH WEEK
Table - 13
VISUAL ACUITY LASER GROUP PLACEBO
6/6-6/9 5(33.33%) 0
6/12-6/18 9(60%) 10(66.67)
<6/18 1(6.667%) 5(33.33%)
0%
10%
20%
30%
40%
50%
60%
70%
80%
6/6-6/9 6/12-6/18 <6/18
laser group
placebo
Best corrected Visual acuity  of 6/6-6/9 was seen in 33.33% of
laser group 0%in the observation group.
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14. POST TREATMENT MACULAR THICKNESS AT 4TH
WEEK
Table - 14
MACULAR
THICKNESS in
µm
LASER GROUP PLACEBO
<200 3(20%) 0
201-300 10(66.67%) 6(40%)
301-400 2(13.33%) 6(40%)
>400 0 3(20%)
0%
10%
20%
30%
40%
50%
60%
70%
<200µ 201-300µ 301-400µ >400µ
Laser group
placebo
Average reduction in the central macular thickness in subgroup 1
at the end of 4th week was 157µm, whereas in subgroup 2, it was
56.87µm.
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15. VISUAL ACUITY AT 12TH WEEK
Table - 15
VISUAL ACUITY LASER GROUP PLACEBO
6/6-6/9 12(80%) 2(13.33%)
6/12-6/18 3(20%) 10(66.67%)
<6/18 0% 3(20%)
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
6/6-6/9 6/12-6/18 <6/18
laser group
placebo
Best corrected visual acuity of 6/6-6/9 was noted in 80% in the
subgroup 1, whereas only 13.33% had visual acuity of 6/6-6/9 in
subgroup 2.
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16. MACULAR THICKNESS POST TREATMENT AT 12TH
WEEK
Table - 16
MACULAR
THICKNESS
LASER GROUP PLACEBO
<200 9(60%)
201-300 5(33.33%) 10(66.66%)
>300 1(6.66%) 5(33.33%)
0%
10%
20%
30%
40%
50%
60%
70%
<200 201-300 >300
laser group
placebo
Average reduction in the central macular thickness in subgroup 1
at the end of 12th week was 186µm,whereas in subgroup 2, it was
98.87µm.
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PATIENT VELMURUGAN OS-CSCR
PRE-TREATMENT  THICKNESS
LE - TOPOGRAPHY
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VELMURUGAN-OS-CSCR
POST-TREATMENT THICKNESS 4TH WEEK
LE - TOPOGRAPHY
56
VELMURUGAN-OS-CSCR
POST-TREATMENT 12TH WEEK
LE - TOPOGRAPHY
57
DISCUSSION AND RESULTS
1. In our study of 50 patients the age group affected was between 20
and 50 years. Previous studies showed involvement between 20
and 50years of age (Gass,et.al).11
2. Male:female ratio  was 9:1.
David A.Quillenet al., observed that women tend to be older at
the time of onset when compared to men, since in our study only
one female has been reported and the difference in age groups
cannot be found out so this emphasis could not be proved.
3. In our study though the incidence of Central serous retinopathy
was more in the left eye (52%), there was no significant
difference between the eyes involved and there was no
predilection for the eye involvement. 4% of the patients had
bilateral involvement.
4. All patients presented to us with defective central vision, about
60% of patients gave characteristic central scotoma, remaining
40% patient had metamorphopsia.
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5. The recurrence rate of CSCR in our study was seen in 30% of the
patients and the interval between the previous and the present
episode ranged from 4 months to 3 years.
About 53.33% of patients had recurrence within the period of 6
months. About 10% of patients had persistent disease of duration
>4months. The incidence of recurrence was more in patient with
mental stress though it could’nt be quantified.
Gass et al observed recurrences in 20-30% of patients.11
6. History of steroid usage as systemic, topical and ointment form
was seen in 10% patients. The remaining 90% gave no history of
steroid usage but had history of increased mental stress.
7. The best corrected visual acuity at the time of presentation ranged
from 6/6-6/60.
In 52% of patients the corrected visual acuity was between 6/12-
6/24.
8. Various Fundus fluorescein angiographic patterns were studied,
of which the Ink blot pattern was seen in 50%, smoke stack
pattern in 28%, retinal pigment epithelial changes seen in 10%,
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pigment epithelial detachment association was seen in 10%, 2%
(one patient) had multifocal leakage and there was a history of
steroid usage in him.
9. Location of leakage in fluorescein angiography showed that 40%
was within the foveal avascular zone or within 375µm from the
centre of fovea, 20% in the inferotemporal quadrant of macula, In
18% the leakage was in the superonasal quadrant, In 16% the
leakage in the superotemporal quadrant and in 6%, the inferonasal
quadrant.
Bennet, G., observed that the overall incidence of leakage points
was greatest in the upper nasal quadrant, followed by lower nasal
quadrant, the upper temporal quadrant and the lower temporal
quadrant in decreasing order of frequency.13
10. Optical coherence tomography was helpful in quantification of
serous detachment. Central Macular thickness was 200-300µm in
26.66% of  the  patients, in about 46.66% thickness ranged 301-
400µm, in 6.66% the thickness was 401-500µm, in about 20% the
macular thickness was about >500µm. It was further observed
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that pigment epithelial detachment was present in only 5% of the
patients.
Although association of PED facilitated the pathogenesis of
central serous chorioretinopathy. It was not observed in majority
of patients studied.
11. Subgroup 1, 15 patients with leak 375µm away from the fovea
were treated with laser photocoagulation. It was observed that
60% regained 6/6-6/9 vision within a period of 4 weeks whereas
no (0%) patient in subgroup 2 had 6/6-6/9 vision. This study is
supported by Early laser photocoagulation in patients with CSCR,
by V.Strum, R.Schwartz & G.Richard Ophthalmology university
of  Hamburg,Germany.30
12. Visual acuity observed at 12 weeks showed that 73.33%  regained
6/6-6/9 vision whereas only 13.33% patients in control group
regained 6/6-6/9 vision. This observation is supported by Early
Laser photocoagulation in patients with CSCR, Department of
Ophthalmology, Hospital of Zurich, Switz.
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13. Average reduction in the central macular thickness in subgroup 1
at the end of 4th week was 157µm, whereas in subgroup 2, it was
56.87µm.
14. Average reduction in central macular thickness in the subgroup
1(study group) at the end of 12th week was 186µm,    whereas in
subgroup 2, it was 98.87µm.
15. About 60% of patients in the sub group 1 had complete resolution
of serous detachment at the end of 12 weeks, whereas the
remaining 40% had residual detachment inspite of response to
treatment due high pretreatment macular thickness.
16. Thickness in the range of 201-300µ was noted in 66.67% of the
Subgroup 2.No patient had complete resolution at the end of 12
weeks as compared to laser treatment group.
17. The statistical analysis for the macular thickness at 4 weeks
showed significant probability chi-square test of 0.029% and
o.oo2% at 12 weeks
18. The statistical analysis for the visual acuity at 4 weeks showed
significant probability chi-square test of 0.041% and 0.017% at
12 weeks.
62
CONCLUSION
CENTRAL SEROUS CHORIORETINOPATHY predominantly
affects healthy male (90%).
Ink blot pattern is the most common fluorescein pattern found in
the study (50%).
OCT helps in quantification of macular thickness and look for
association of pigment epithelial detachment and choroidal
neovascularisation.
Early Laser photocoagulation is effective in rapid restoration of
vision and reduction in macular thickness within a period of 12 weeks,
and there is no complication reported in our study due to laser
treatment.
Photocoagulation play major role in  rapid  restoration  of  vision
6/6-6/9  within period of 12 weeks in about 73.33%, whereas only
13.33% of the patient in placebo group had 6/6-6/9 vision.
Early laser photocoagulation results in rapid visual restoration
within a period which ranged from 2-12weeks.
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The recurrence rate of CSCR in our study was 30% and the
interval between previous and present episodes ranged from 4 months to
3 years by prospective and retrospective analysis. About 10% of patients
had persistent disease of duration more than 4 months.
Majority of patients gave history of increased mental stress.
History of steroid usage either systemic, topical or inhalers and
ointment was noted in minority of patients(10%).
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LIMITATIONS
Post laser recurrences of CSCR could not be documented
with follow up period of 4th weeks and 12th weeks.
Furthermore late post laser complications such as CNVM could be
identified only by extended follow up.
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PART THREE
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PROFORMA
NAME
AGE/SEX                                       SERIAL NO
OP NO
ADDRESS
PHONE NO
OCCUPATION
COMPLAINTS
Defective vision
Central scotoma
Metamorphopsia/Micropsia
Headache /others
HISTORY
1. Past eye illness
Similar episode
Duration of recurrence
2.Personal History
Mental stress Allergy
Smoking DRUG INTAKE
3.Systemic Illness
EXAMINATION OF EYE
Visual Acuity
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Anterior Segment
Tension
Amsler Grid
Fundus  examination
Direct Ophthalmoscopy
Slit lamp biomicroscopy with 90D
Fundus Fluorescein Angiography
Pattern- Ink Blot/Smoke Stack/Multifocal Leak
RPE changes
Site Of Leak
FAZ
Elsewhere In Macula
OPTICAL COHERENCE TOMOGRAPHY
Central Macular Thickness
RE/LE
PED - YES/NO
GENERAL EXAMINATION
Anemia
Focal sepsis
ENT
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DENTAL
INVESTIGATION
Hb%
TC-
DC-
ESR-
Mx
VDR
TREATMENT
LASER PHOTOCOAGULATION
PLACEBO THERAPY
FOLLOW UP
DATE
VISION
CENTRAL MACULAR THICKNESS
AMSLER GRID CHART
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KEY TO MASTER  CHART
SEX
M - Male
F - Female
EYE AFFECTED
RE - Right eye
LE - Left eye
D.V - Defective vision
AMSLER’S CHARTING
C.S - Central scotoma
M - Micropsia
MM - Metamorphopsia
PREVIOUS ATTACK
S.E - Same eye
O.E - Other eye
VISUAL ACUITY
NIP - No improvement with pinhole
PH - Pinhole
P - Partial
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ATTACK INTERVAL
M - Months
S.U. - STEROID USAGE
FUNDUS FLUORESCEIN ANGIOGRAPHY PATTERN
I.B.P - Ink Blot Pattern
S.S.P - Smoke Stack Pattern
RPE C - Retinal pigment epithelial changes
PED - Pigment epithelial detachment.
FUNDUS FLUORESCEIN LEAK PATTERN
FAZ - Foveal avascular zone
ITQ - Infero temporal quadrant
INQ - Inferonasal quadrant
SNQ - Superonasal quadrant
STQ - Superotemporal quadrant
OPTICAL COHERENCE TOMOGRAPHY (OCT)
PED - Pigment epithelial detachment
C.M.T.O.A.E - Central Macular thickness of affected eye.
CNVM - Choroidal neovascularisation.
S.G - Subgroup
MASTER CHART
sg
C.S MM/M S.E O.E INTERVAL R.E L.E I.B.P S.S.P RPE C. PED FAZ ITQ INQ STQ SNQ PED C.M.T.O.A.E CNVM 4TH  WK 12 WK 4TH WK 12 WK
1 GOPI 29 M RE YES YES NO YES 5M 6/9P 6/6P NO YES NO NO NO YES NO NO NO NO NO NO
2 NARAYANASWAMY 40 M RE YES YES NO 6/18NIP 6/12PH6/6 NO NO NO NO NO NO NO NO YES NO NO 270 NO 1 6/9NIP 6/6P 197 185
3 KARTHICK 50 M LE YES YES NO 6/24NIP 6/18NIP NO YES NO NO NO NO YES NO NO NO NO 334 NO 2 6/18NIP 6/18NIP 317 308
4 BHASKAR 44 M LE YES YES NO 6/12PH6/6 6/24NIP NO YES NO NO NO NO NO NO NO YES NO 384 NO 1 6/9NIP 6/9NIP 234 204
5 NARAYANASWAMY 27 M LE YES NO YES 6/6P 6/18NIP YES YES NO NO NO NO YES NO NO NO NO 400 NO 2 6/18NIP 6/12NIP 380 350
6 RAJA 23 M LE YES NO YES YES 12M 6/9P 6/12NIP NO YES NO NO NO YES NO NO NO NO NO NO
7 MEENAKSHI 45 F RE YES YES NO YES 6M 6/36NIP 6/24PH6/12 NO YES NO NO NO YES NO NO NO NO NO NO
8 DASARATHAN 27 M RE YES YES NO 6/12NIP 6/12NIP NO NO YES NO NO NO NO NO YES NO NO 287 NO 2 6/12NIP 6/9NIP 275 250
9 KESAVAN 33 M LE YES NO YES YES 18M 6/12PH6/9 6/12NIP NO NO YES NO NO YES NO NO NO NO NO NO
10 VELMURUGAN 29 M LE YES YES NO 6/9P 6/18NIP NO NO YES NO NO NO YES NO NO NO NO 584 NO 1 6/12NIP 6/9NIP 321 208
11 SUNDARAJAN 31 M LE YES YES NO 6/18PH6/6 6/24NIP NO YES NO YES NO NO NO YES NO NO NO 344 NO 2 6/24NIP 6/18NIP 300 280
12 RAVI 23 M LE YES YES NO YES 6M 6/9P 6/18NIP NO NO YES NO NO YES NO NO NO NO NO NO
13 SEKAR 29 M RE YES NO YES YES 5M 6/18NIP 6/12P NO NO YES NO NO YES NO NO NO NO NO NO
14 NATARAJAN 35 M RE YES NO YES 6/18NIP 6/24PH6/9 NO NO YES NO NO NO NO NO NO YES NO 340 NO 1 6/9NIP 6/6P 204 190
15 SRINIVASAN 40 M RE YES NO YES 6/12NIP 6/24PH6/12 NO YES NO NO NO NO YES NO NO NO NO 278 NO 2 6/12NIP 6/9NIP 240 215
16 VASUDEVAN 47 M RE YES NO YES 6/36NIP 6/36PH6/18 NO NO YES NO NO NO NO NO NO YES NO 600 NO 1 6/24NIP 6/18NIP 400 250
17 XAVIER 21 M RE YES YES NO 6/24NIP 6/6P NO NO YES NO NO NO YES NO NO NO NO 430 NO 2 6/24NIP 6/18NIP 350 295
18 RAMESH 32 M LE YES NO YES YES 12M 6/12PH6/6 6/12NIP YES YES NO NO NO YES NO NO NO NO NO NO
19 VINOTH 35 M LE YES NO YES 6/12NIP 6/24NIP NO NO YES NO NO NO NO NO YES NO NO 367 NO 1 6/12NIP 6/9NIP 210 192
20 VENKATESH 40 M RE YES NO YES 6/24NIP 6/18PH6/9 NO NO YES NO NO NO NO NO NO NO NO 375 NO 2 6/18NIP 6/12NIP 325 280
21 MANOHAR 43 M LE YES YES NO 6/9PH6/6 6/36NIP NO YES NO NO NO NO NO YES NO NO NO 618 NO 1 6/18NIP 6/12NIP 400 280
22 MOORTHY 29 M RE YES YES NO 6/36NIP 6/6P NO YES NO NO NO NO YES NO NO NO NO 706 NO 2 6/36NIP 6/24NIP 650 504
23 VELU 36 M RE YES NO YES YES 12M 6/12NIP 6/9NIP NO NO YES NO NO YES NO NO NO NO NO NO
24 SAIRAM 38 M LE YES YES NO YES 6M 6/12PH6/9 6/18NIP NO NO YES NO NO YES NO NO NO NO NO NO
25 GOPAL 40 M LE YES YES NO 6/12PH6/9 6/18NIP NO YES NO NO NO NO NO NO NO YES NO 376 NO 2 6/12NIP 6/12NIP 326 300
26 KUMARI 40 F LE YES YES NO 6/18PH6/9 6/24NIP NO YES NO YES NO NO NO NO NO YES NO 280 NO 1 6/9NIP 6/6P 198 187
27 RAJENDARAN 48 M RE YES YES NO YES 5M 6/36NIP 6/24PH6/9 YES YES NO NO NO YES NO NO NO NO NO NO
28 MURUGAN 35 M LE YES NO YES 6/12PH 6/6 6/18NIP NO NO YES NO NO NO NO NO NO YES NO 380 NO 2 6/18NIP 6/12NIP 340 300
29 SURESH 32 M RE YES YES NO YES 6M 6/12NIP 6/12PH6/6 NO YES NO NO YES YES NO NO NO NO YES NO
30 ESWARI 37 F LE YES NO YES YES 24M 6/12PH6/6 6/12NIP NO NO YES NO NO YES NO NO NO NO NO NO
31 RAJU 39 M RE YES YES NO 6/18NIP 6/12NIP NO YES NO NO NO NO YES NO NO NO NO 390 NO 1 6/12PH6/6 6/9PH6/6 210 186
32 LINGUSAMY 45 M LE YES YES NO 6/24PH6/12 6/24NIP NO YES NO NO NO NO NO YES NO NO NO 450 NO 1 6//12PH6/9 6/9PH6/6 250 202
33 CHELLAMUTHU 35 M LE YES YES NO 6/12PH6/6 6/12NIP NO NO YES YES NO NO NO NO YES NO NO 275 NO 2 6/12NIP 6/12NIP 260 260
34 RAMESH 27 M RE YES NO YES 6/36NIP 6/6P YES YES NO NO NO YES NO NO NO NO NO NO
35 ANANDAN 29 M RE YES YES NO 6/18NIP 6/6P NO YES NO NO NO NO NO NO NO YES NO 376 NO 1 6/12PH6/9 6/9PH6/6 212 197
36 ASHOK 33 M LE YES NO YES YES 5M 6/12PH6/6 6/12NIP NO NO YES YES YES YES NO NO NO NO YES NO
37 GOPI 25 M RE YES NO YES 6/24NIP 6/6P NO NO YES NO NO NO NO NO NO YES NO 400 NO 1 6/18PH6/12 6/12PH6/6 240 212
38 GANESAN 40 M LE YES YES NO YES 36M 6/24PH6/12 6/36NIP NO YES NO NO NO YES NO NO NO NO NO NO
39 CHINNAIH 27 M RE YES NO YES 6/18NIP 6/6P NO NO YES NO NO NO YES NO NO NO NO 334 NO 1 6/12PH6/9 6/9PH6/6 240 194
40 AMULRAJ 34 M RE YES YES NO 6/60NIP 6/24PH6/6 NO YES NO NO NO NO NO NO YES NO NO 396 NO 1 6/12NIP 6/12NIP 234 190
41 SUNDARI 31 F LE YES NO YES YES 24M 6/12NIP 6/24NIP YES NO YES NO NO YES NO NO NO NO NO NO
42 KUMAR 27 M RE YES YES NO 6/18NIP 6/9PH6/6 NO YES NO NO NO NO NO NO YES NO NO 277 NO 2 6/18PH6/12 6/12NIP 260 250
43 RAVI 25 M LE YES YES NO 6/9PH6/6 6/18NIP NO NO YES NO YES YES NO NO NO NO YES NO
44 KRISHNAMOORTHY 40 M LE YES YES NO 6/18P 6/18NIP NO YES NO NO NO YES NO NO NO NO NO NO
45 THANDAVARAYAN 47 M RE YES NO YES 6/24NIP 6/36PH6/18 NO YES NO NO NO NO YES NO NO NO NO 624 NO 2 6/36NIP 6/36PH6/24 598 503
46 LOGU 36 M LE YES YES NO 6/9PH6/6 6/36NIP NO YES NO NO NO YES NO NO NO NO NO NO
47 RAMKUMAR 40 M LE YES YES NO 6/12NIP 6/12NIP NO NO YES YES NO NO NO NO YES NO NO 265 NO 1 6/9PH6/6 6/6P 200 180
48 RAJESH 46 M RE YES YES NO 6/12NIP 6/24PH6/9 NO YES NO NO NO NO YES NO NO NO NO 289 NO 2 6/12NIP 6/12NIP 260 249
49 LAKSHMI 55 F BE YES NO YES 6/60NIP 6/24NIP NO YES NO NO NO YES NO NO NO NO NO NO
50 MANI 31 M LE YES YES NO 6/24PH6/12 6/36NIP NO YES NO NO YES NO NO NO YES YES YES 676 NO 6/36NIP 6/24NIP 590 501
OCT PATTERN V.A MACULAR
THICKNESS
AMSLER'S
CHART
PREVIOUS ATTACK BEST CORRECTED
VISUAL ACUITY S.U
FFA PATTERN FFA LEAK AREAS
D.VS.NO. NAME AGE SEX
EYE
AFFECTED
